

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

13 Jun 2026

### Investigation of the effect of cocoa powder on fatigue severity in patients with multiple sclerosis (MS) in comparison with placebo effect

#### Protocol summary

##### Study aim

The effect of oral cocoa powder on symptoms of fatigue among patients with multiple sclerosis (MS) compared to placebo

##### Design

A clinical trial without a control group, triple blinded, randomized

##### Settings and conduct

The study is a randomized, tripple-blind clinical trial for 2 months in MS patients referred to Kashani hospital neurology. The drug will be taken 25 g daily in the morning and afternoon doses. Patients will take the drug regularly for eight weeks. If you forget a dose of the drug, you can take the drug for an hour later, and if you forget the drug for more than one hour, reapply for the next hour. If the drug is not taken for two consecutive days or forgotten for a total of 10 doses, these patients will be excluded.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Consent to participate in the study; MS with Relapsing remitting form; Less than 10 years have passed since their diagnosis; Age between 20 and 50 years; Have a Fatigue severity scale above 4; The EDSS score is below 6; Have a recent anemia and hypothyroid rejection test in one month; Exclusion criteria: Have recurrent in the past 3 months; The disease involves the CNS except migraine; They have acute febrile illness; Have systemic autoimmune disease; Based on Beck Depression Inventory moderate or severe (Questionnaire score above 20); Currently taking neurotoxic drugs including: antipsychotic agents, monoamine oxidase inhibitors, benzodiazepines, tricyclic antidepressant drugs, anticonvulsants, beta blockers and barbiturates

##### Intervention groups

We have two intervention groups. The first group received the drug in the form of 12.5 grams of cocoa powder, and the second group received a placebo containing 2.5 grams of cocoa powder.

##### Main outcome variables

Fatigue

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20171030037093N34**

Registration date: **2020-03-28, 1399/01/09**

Registration timing: **prospective**

Last update: **2020-03-28, 1399/01/09**

Update count: **0**

##### Registration date

2020-03-28, 1399/01/09

##### Registrant information

##### Name

Sadra Ansari pour

##### Name of organization / entity

Shahrekord University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 31 3650 3487

##### Email address

st\_ansari.s@skums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2020-03-30, 1399/01/11

##### Expected recruitment end date

2020-06-29, 1399/04/09

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**

empty

**Scientific title**

Investigation of the effect of cocoa powder on fatigue severity in patients with multiple sclerosis(MS) in comparison with placebo effect

**Public title**

The effect of cocoa powder on fatigue in multiple sclerosis patients

**Purpose**

Diagnostic

**Inclusion/Exclusion criteria****Inclusion criteria:**

Consent to participate in the study MS with Relapsing remitting form Less than 10 years have passed since their diagnosis Age between 20 and 50 years Have a Fatigue severity scale above 4. The EDSS score is below 6 Have a recent anemia and hypothyroid rejection test in one month

**Exclusion criteria:**

Have recurrent in the past 3 months The disease involves the CNS except migraine They have acute febrile illness Have systemic autoimmune disease Based on Beck Depression Inventory moderate or severe (Questionnaire score above 20) Currently taking neurotoxic drugs including: antipsychotic agents, monoamine oxidase inhibitors, benzodiazepines, tricyclic antidepressant drugs, anticonvulsants, beta blockers and barbiturates

**Age**

From **20 years** old to **50 years** old

**Gender**

Both

**Phase**

2

**Groups that have been masked**

- Participant
- Investigator
- Data analyser

**Sample size**

Target sample size: **60**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Patients in the study were randomly assigned to either A or B groups using computer software.

**Blinding (investigator's opinion)**

Triple blinded

**Blinding description**

At first the drug powder and placebo optionally into groups A and B are packed without the knowledge of a physician, patient, or analyzer (note that only the first person knows that package A is the drug or placebo). The software is divided into recipient groups A and recipient B, which will be written in the form A or B. After completing the design and final analysis, the packaging person announces that A B Which powder (drug or placebo) each had. According to this physician, the patient and the analyzer were unaware of the groups

until after the data was analyzed

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics Committee of Isfahan University of Medical Sciences

**Street address**

Isfahn University of Medical Sciences, Hezar Jerib Avenue, Isfahan

**City**

Isfahan

**Province**

Isfahan

**Postal code**

7346181746

**Approval date**

2019-11-26, 1398/09/05

**Ethics committee reference number**

IR.MUI.MED.REC.1398.445

**Health conditions studied****1****Description of health condition studied**

Multiple sclerosis

**ICD-10 code**

G35

**ICD-10 code description**

Multiple sclerosis

**Primary outcomes****1****Description**

Fatigue

**Timepoint**

Before and after the study

**Method of measurement**

With MFIS and FSS questionnaires

**Secondary outcomes**

empty

**Intervention groups**

## 1

### Description

Intervention group: The drug will be administered in the form of 12.5 grams of cocoa powder after dissolving in a glass of water half an hour before or one hour after meals.

### Category

Treatment - Drugs

## 2

### Description

Control group: receive placebo. Each placebo pack contains 2.5 grams of cocoa powder (much less than the effective and therapeutic dose of cocoa) that can be used in 200 cc of boiling water or milk.

### Category

Treatment - Drugs

## Recruitment centers

## 1

### Recruitment center

#### Name of recruitment center

Kashani hospital

#### Full name of responsible person

Iman Adibi

#### Street address

Kashani Street, Isfahan Province, Isfahan

#### City

Isfahan

#### Province

Isfahan

#### Postal code

7346181746

#### Phone

+98 31 3792 7539

#### Email

i.adibi@gmail.com

## Sponsors / Funding sources

## 1

### Sponsor

#### Name of organization / entity

Esfahan University of Medical Sciences

#### Full name of responsible person

Shaghayegh Haghjooy Javanmard

#### Street address

Isfahan University of Medical Sciences, Hezar Jerib Avenue

#### City

Isfahan

#### Province

Isfahan

#### Postal code

7346181746

#### Phone

+98 31 3668 0048

### Email

sh\_haghjoo@med.mui.ac.ir

### Grant name

### Grant code / Reference number

### Is the source of funding the same sponsor organization/entity?

Yes

### Title of funding source

Esfahan University of Medical Sciences

### Proportion provided by this source

100

### Public or private sector

Public

### Domestic or foreign origin

Domestic

### Category of foreign source of funding

empty

### Country of origin

### Type of organization providing the funding

Academic

## Person responsible for general inquiries

### Contact

#### Name of organization / entity

Esfahan University of Medical Sciences

#### Full name of responsible person

Iman Adibi

#### Position

Associate professor

#### Latest degree

Specialist

#### Other areas of specialty/work

Neurology

#### Street address

Kashani Hospital

#### City

Isfahan

#### Province

Isfahan

#### Postal code

7346181746

#### Phone

+98 31 3792 7539

#### Email

i.adibi@gmail.com

## Person responsible for scientific inquiries

### Contact

#### Name of organization / entity

Esfahan University of Medical Sciences

#### Full name of responsible person

Iman Adibi

#### Position

Associate professor

#### Latest degree

Specialist

#### Other areas of specialty/work

Neurology

#### Street address

Kashani Hospital  
**City**  
Isfahan  
**Province**  
Isfahan  
**Postal code**  
7346181746  
**Phone**  
+98 31 3792 7539  
**Email**  
i.adibi@gmail.com

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Esfahan University of Medical Sciences  
**Full name of responsible person**  
Iman Adibi  
**Position**  
Associate professor  
**Latest degree**  
Specialist  
**Other areas of specialty/work**  
Neurology  
**Street address**  
Kashani Hospital  
**City**  
Isfahan  
**Province**

Isfahan  
**Postal code**  
7346181746  
**Phone**  
+98 31 3792 7539  
**Email**  
i.adibi@gmail.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

### Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

### Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

### Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

### Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

### Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

### Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available